Observational studyPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors.
Observational study in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRapid drug desensitization (RDD) enables the safe reintroduction of chemotherapeutic agents in patients with hypersensitivity reactions (HSRs). However, some patients experience breakthrough reactions (BTRs) during desensitization, and research on factors associated with BTRs is limited in pediatric patients.
methodsWe conducted an ambispective observational cross-sectional study in Bangkok, Thailand. Patients ≤18-year-old who experienced immediate HSRs (within 1-6 h) to chemotherapeutic agents and underwent RDD following evaluation by allergists between January 2010 and April 2025 were included.
resultsA total of 182 RDDs were performed in 38 children (median age of 5.3 years). The majority were diagnosed with acute leukemia (47.4%), and the most common causative agents for HSRs were E. coli-Asparaginase (26.9%), vincristine (24.7%), and methotrexate (13.7%). Asparaginase, vincristine, cyclophosphamide, carboplatin/oxaliplatin, and doxorubicin were commonly associated with Type I HSRs, while methotrexate, cyclosporin A and etoposide were linked to Type I HSRs as well as infusion-related reactions (IRRs) or cytokine-release reactions (CRRs). Twenty-nine BTRs occurred during RDD (15.9%), most of which were mild (72.4%). Independent risk factors for BTRs included E. coli-Asparaginase desensitization (adjusted OR 3.87 [1.45, 10.39], p = .007), and a higher initial starting dose (ratio ≤1:10,000) (adjusted OR 3.51 [1.02, 12.18], p = .048). Conversely, later cycles of desensitization reduced the risk of BTRs (adjusted OR 0.47 [0.31, 0.72], p < .001).
conclusionRDDs for chemotherapeutic agents effectively enable safe treatment continuation in most children with immediate HSRs, including type I HSR, CRR, and mixed reactions. In our study, E. coli-Asparaginase, a higher initial starting dose, and an early desensitization cycle were identified as having potential risk factors associated with BTRs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.